Goldman Sachs Group Inc Transcode Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 14, 2024
SELL
$0.31 - $0.91 $1,240 - $3,640
-4,000 Reduced 23.36%
13,122 $4,000
Q1 2023

May 11, 2023
SELL
$0.31 - $0.91 $1,240 - $3,640
-4,000 Reduced 23.36%
13,122 $4,000
Q4 2022

May 14, 2024
BUY
$0.33 - $984.0 $5,650 - $16.8 Million
17,122 New
17,122 $11,000
Q4 2022

Feb 13, 2023
BUY
$0.33 - $984.0 $5,650 - $16.8 Million
17,122 New
17,122 $11,000

Others Institutions Holding RNAZ

# of Institutions
1
Shares Held
6.5K
Call Options Held
0
Put Options Held
0
View Full List

About Transcode Therapeutics, Inc.

RNAZ Quotes by TradingView
  • Ticker RNAZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,977,200
  • Market Cap $45.7M
  • Description
  • TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...
More about RNAZ
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email